ストックスクリーナーアプリを入手
14.46
3.88%
0.54
Immunovant Inc (IMVT) 最新ニュース
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Northern Trust Corp - Defense World
Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey
The Manufacturers Life Insurance Company Has $889,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Transcript : Immunovant, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com
Dimensional Fund Advisors LP Sells 58,463 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey
Raymond James Financial Inc. Buys Shares of 20,382 Immunovant, Inc. (NASDAQ:IMVT) - Defense World
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Investor’s Delight: Immunovant Inc (IMVT) Closes Weak at 15.22, Down -3.67 - DWinneX
Ins & Outs: Biopharma players shuffle c-suite ranks - BioProcess International
(IMVT) Investment Analysis - news.stocktradersdaily.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Wells Fargo & Company MN - Defense World
A company insider recently sold 1,925 shares of Immunovant Inc [IMVT]. Should You Sale? - knoxdaily.com
IMVT’s Stock Market Adventure: -34.80% YTD Growth Amidst Volatility - investchronicle.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Perhaps timely catching Immunovant Inc (IMVT) would be a good idea - Sete News
Immunovant registers shares for selling stockholders - MSN
Potential Price Increase for Immunovant Inc (IMVT) After Recent Insider Activity - knoxdaily.com
Market Watch Highlights: Immunovant Inc (IMVT) Ends on an Downturn Note at 14.72 - DWinneX
Stock Market Recap: Immunovant Inc (IMVT) Concludes at 14.58, a -7.60 Surge/Decline - DWinneX
Renaissance Technologies LLC Sells 108,100 Shares of Immunovant, Inc. (NASDAQ:IMVT) - The AM Reporter
Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Average PT from Analysts - Defense World
Immunovant’s (IMVT) “Neutral” Rating Reiterated at UBS Group - Defense World
Immunovant Inc [IMVT] Records 50-Day SMA of $18.03 - knoxdaily.com
All change at Immunovant as Pete Salzmann retires - The Pharma Letter
UBS Downgrades Immunovant to Neutral, Price Target is $17 - marketscreener.com
Upward Trajectory: Immunovant Inc (IMVT) Posts a Slidee, Closing at 14.46 - DWinneX
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated - Asianet Newsable
Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com
Immunovant Names New CEO, CFO - marketscreener.com
Roivant Sciences Announces Leadership Changes at Immunovant - TipRanks
Immunovant Announces New CEO Amid Strategic Shift - TipRanks
Immunovant (IMVT) Appoints New CEO Amid Strategic Changes - GuruFocus
Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - TradingView
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - The Manila Times
Immunovant (IMVT) Announces Leadership Changes - StreetInsider
Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan
Alliancebernstein L.P. Grows Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
(IMVT) On The My Stocks Page - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com
Wellington Management Group LLP Lowers Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant CEO Peter Salzmann sells shares worth $364,941 By Investing.com - Investing.com South Africa
Raymond James Financial Inc. Takes Position in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant CEO Peter Salzmann sells shares worth $364,941 - Investing.com
Immunovant CEO Peter Salzmann Sells Shares to Cover Tax Obligations - TradingView
JPMorgan Chase & Co. Has $28.57 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Immunovant stock hits 52-week low at $13.58 amid market challenges - Investing.com Australia
Immunovant stock hits 52-week low at $13.58 amid market challenges By Investing.com - Investing.com South Africa
Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? - Insider Monkey
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):